Bioxcel Therapeutics Inc (BTAI) Stock Price, Quote & News

Company Profile

BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States. The company IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. It also develops its neuroscience candidate, BXCL501, which is an investigational, proprietary, orally...

Industry: Biotechnology

Sector: Healthcare

Phone: 475 238 6837

Website: www.bioxceltherapeutics.com

Address:

555 Long Wharf Drive, 12th Floor, New Haven, United States

Reactors Nov. 17 at 12:09 AM

$BTAI swinging

0 · Reply

HedgeAlerts Nov. 16 at 9:58 PM

Hedge Alert Live - Protect Your Portfolio Contract: $BTAI $1.50 Put · JAN 16, 2026 Exp Entry Price: $0.75 - $4.50 Exit Price Target: $1.67 Profit Margin: +123% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

MoneyGroupLLC Nov. 16 at 2:27 PM

Enter: $BTAI Calls Strike Price: $2 Expiry Date: JAN 16 2026 Buy in Price: $0.15 - $0.30 Sell Price: $0.22 Profit : +48% (Turn every $1 into $1.48) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

HedgeAlerts Nov. 15 at 10:01 PM

0 · Reply

MoneyGroupLLC Nov. 15 at 10:14 AM

0 · Reply

LiquidThetaOptions Nov. 15 at 7:26 AM

💎 LiquidTheta® Live Actionable Trade Asset: $BTAI Contracts: $BTAI January 16, 2026 $2 Calls Scale in: $0.15- $0.18 Scale out: $0.57-$0.97 Profit Potential : 257% ROI Blended Join 💎 Here: https://liquidtheta.com

0 · Reply

PolyesterJacket Nov. 14 at 9:35 PM

$BTAI I finally averaged down to $66. Now if it just hits this price target, I can break even! Hooray!

3 · Reply

HedgeAlerts Nov. 14 at 5:43 PM

Hedge Alert Live - Protect Your Portfolio Contract: $BTAI $1.50 Put · JAN 16, 2026 Exp Entry Price: $0.75 - $4.50 Exit Price Target: $1.23 Profit Margin: +64% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

FoobarSwopey Nov. 14 at 5:11 PM

$BTAI i guess the new high for a while is $1.70? ...pathetic

0 · Reply

BurntReynolds Nov. 14 at 4:46 PM

$BTAI

0 · Reply

BioXcel Therapeutics Reports Third Quarter 2025 Financial Results and Provides Update on Late-Stage Clinical Programs for Agitation in Bipolar, Schizophrenia, and Alzheimer's Disease

Oct 24, 2025, 11:38 AM EDT - 23 days ago

Halper Sadeh LLC Encourages BioXcel Therapeutics, Inc. Shareholders to Contact the Firm to Discuss Their Rights

Oct 14, 2025, 7:00 AM EDT - 4 weeks ago

BioXcel Therapeutics Announces Positive Results from Correlation Study Supporting SERENITY At-Home Exploratory Efficacy Outcomes

Oct 13, 2025, 7:00 AM EDT - 4 weeks ago

BioXcel Therapeutics to Ring Nasdaq Closing Bell on October 14 to Celebrate a Transformative Milestone in Neuroscience Innovation

Sep 18, 2025, 7:00 AM EDT - 2 months ago

BioXcel Therapeutics Regains Compliance with Nasdaq Market Value of Listed Securities Requirements

Sep 10, 2025, 6:41 PM EDT - 2 months ago

BioXcel Therapeutics, Inc. (BTAI) Discuses On SERENITY At-Home Pivotal Phase 3 Safety Trial Results Call (Transcript)

Sep 10, 2025, 3:08 PM EDT - 2 months ago

BioXcel Drug Calms Agitation At Home For Schizophrenia, Bipolar Patients

Sep 10, 2025, 6:30 AM EDT - 2 months ago

BioXcel Therapeutics Reports Positive Topline Exploratory Efficacy Data from SERENITY At-Home Pivotal Phase 3 Safety Trial for Agitation Associated with Bipolar Disorders or Schizophrenia

Sep 4, 2025, 7:00 AM EDT - 2 months ago

BioXcel Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 27, 2025, 12:01 PM EDT - 2 months ago

BioXcel Seeks FDA Label Expansion For Schizophrenia Treatment

Aug 27, 2025, 8:00 AM EDT - 2 months ago

UPDATE -- BioXcel Therapeutics Announces SERENITY At-Home Pivotal Phase 3 Safety Trial Met its Primary Endpoint in Support of sNDA Submission for Label Expansion of IGALMI®

Aug 27, 2025, 7:29 AM EDT - 2 months ago

BioXcel's agitation drug meets main goal in at-home study

Aug 27, 2025, 7:00 AM EDT - 2 months ago

BioXcel Therapeutics Announces SERENITY At-Home Pivotal Phase 3 Safety Trial Met its Primary Endpoint in Support of sNDA Submission for Label Expansion of IGALMI®

Aug 26, 2025, 4:00 PM EDT - 2 months ago

BioXcel Therapeutics To Announce Topline Results from SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia on August 27, 2025

Aug 19, 2025, 7:00 AM EDT - 3 months ago

BioXcel Therapeutics Announces Database Lock in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

Aug 18, 2025, 7:00 AM EDT - 3 months ago

BioXcel Therapeutics Announces Positive FDA Pre-sNDA Meeting Comments for sNDA Submission for BXCL501 in Agitation Associated with Bipolar Disorders or Schizophrenia

Aug 13, 2025, 7:00 AM EDT - 3 months ago

BioXcel Therapeutics to Participate in the H.C. Wainwright & Co. “HCW@Home” Series

Aug 12, 2025, 7:55 AM EDT - 3 months ago

BioXcel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Updates

Aug 11, 2025, 7:00 AM EDT - 3 months ago

BioXcel Therapeutics to Participate in Canaccord Genuity 45th Annual Growth Conference

Aug 6, 2025, 7:00 AM EDT - 3 months ago

BioXcel Therapeutics Announces Publication in Frontiers in Pharmacology on the Effects of Dexmedetomidine (the active ingredient in BXCL-501) on Stress-Mediated Behaviors in Non-clinical Studies

Aug 1, 2025, 7:00 AM EDT - 3 months ago

BioXcel Therapeutics Announces Last Patient Last Visit in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

Jul 21, 2025, 7:00 AM EDT - 4 months ago

BioXcel Therapeutics Submits Pre-Supplemental New Drug Application Meeting Package in Support of Potential Label Expansion for IGALMI®

Jul 1, 2025, 7:00 AM EDT - 4 months ago

BioXcel Therapeutics Receives Second Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

May 27, 2025, 8:01 AM EDT - 6 months ago

BioXcel Therapeutics Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

May 27, 2025, 7:00 AM EDT - 6 months ago

BioXcel Therapeutics Granted Extension to Regain Compliance with Nasdaq Continued Listing Requirement

May 12, 2025, 7:00 AM EDT - 6 months ago

BioXcel Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Mar 27, 2025, 7:00 AM EDT - 8 months ago

BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2024

Mar 11, 2025, 7:00 AM EDT - 8 months ago

BioXcel Therapeutics Strengthens Cash Position to Advance SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

Mar 7, 2025, 7:00 AM EST - 9 months ago

BioXcel Therapeutics Announces 33% Enrollment in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

Mar 4, 2025, 4:15 PM EST - 9 months ago

BioXcel Therapeutics Announces Closing of $14 Million Registered Direct Offering

Mar 3, 2025, 3:33 PM EST - 9 months ago

BioXcel Therapeutics Announces $14 Million Registered Direct Offering

Mar 3, 2025, 7:00 AM EST - 9 months ago

BioXcel Therapeutics Announces FDA Closed its Inspection of Site for Phase 3 TRANQUILITY II Trial for Acute Treatment of Agitation Associated with Alzheimer's Dementia

Feb 28, 2025, 7:00 AM EST - 9 months ago

BioXcel Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule

Feb 6, 2025, 7:00 AM EST - 10 months ago

BioXcel Therapeutics Announces Reverse Stock Split

Nov 22, 2024, 8:16 AM EST - 1 year ago

BioXcel Therapeutics Announces Pricing of $7.0 Million Public Offering

Nov 21, 2024, 4:47 PM EST - 1 year ago

BioXcel Therapeutics Announces Proposed Public Offering

Nov 14, 2024, 9:07 AM EST - 1 year ago

BioXcel Therapeutics, Inc. (BTAI) Q3 2024 Earnings Call Transcript

Nov 8, 2024, 7:00 AM EST - 1 year ago

BioXcel Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024

Oct 29, 2024, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics to Present at ThinkEquity Conference

Oct 15, 2024, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics Announces U.S. Department of Defense Grant to University of North Carolina to Fund Study of BXCL501 (Sublingual Dexmedetomidine) for Treating Acute Stress Disorder

Sep 19, 2024, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics Announces Clinical Prioritization and Update on BXCL501 Late-Stage Programs for Agitation

Sep 5, 2024, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics Announces Initiation of SERENITY At-Home Pivotal Phase 3 Safety Trial of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

Aug 9, 2024, 9:48 PM EDT - 1 year ago

BioXcel Therapeutics, Inc. (BTAI) Q2 2024 Earnings Call Transcript

Jul 16, 2024, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics Announces Preliminary Estimated Unaudited Second Quarter Net Revenues from Sales of IGALMI™ (dexmedetomidine) Sublingual Film

May 28, 2024, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics to Present at Jefferies Global Healthcare Conference

May 21, 2024, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics Announces Oral and Poster Presentations at the 2024 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting

May 9, 2024, 9:53 AM EDT - 1 year ago

BioXcel Therapeutics, Inc. (BTAI) Q1 2024 Earnings Call Transcript

May 9, 2024, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics Reports First Quarter 2024 Financial Results

Apr 25, 2024, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics to Report First Quarter 2024 Financial Results on May 9, 2024

Apr 24, 2024, 10:30 AM EDT - 1 year ago

BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meeting

Reactors Nov. 17 at 12:09 AM

$BTAI swinging

0 · Reply

HedgeAlerts Nov. 16 at 9:58 PM

0 · Reply

MoneyGroupLLC Nov. 16 at 2:27 PM

0 · Reply

HedgeAlerts Nov. 15 at 10:01 PM

0 · Reply

MoneyGroupLLC Nov. 15 at 10:14 AM

0 · Reply

LiquidThetaOptions Nov. 15 at 7:26 AM

0 · Reply

PolyesterJacket Nov. 14 at 9:35 PM

$BTAI I finally averaged down to $66. Now if it just hits this price target, I can break even! Hooray!

3 · Reply

HedgeAlerts Nov. 14 at 5:43 PM

0 · Reply

FoobarSwopey Nov. 14 at 5:11 PM

$BTAI i guess the new high for a while is $1.70? ...pathetic

0 · Reply

BurntReynolds Nov. 14 at 4:46 PM

$BTAI

0 · Reply

Bob584 Nov. 14 at 4:42 PM

$BTAI Shorts returned 8,000 of my shares yesterday.

0 · Reply

Futuresbright22 Nov. 14 at 2:33 PM

$BTAI I would like to confirm that I do have high hopes and I am deeply invested in BTAI. I believe this will be successful and I appreciate the opportunity to discuss read and share information. I have zero intention of bringing any negative or false information to mislead others and sincerely hope nothing but success to all who share these intentions.

2 · Reply

SrTxan Nov. 14 at 2:29 PM

$BTAI I've been analyzing the transactions that have occurred since Murchison acquired the warrants, and it's quite possible that Integrated Core Strategies (Millenium) purchased its million shares using Murchison's convertible warrants. Either Murchison converted its warrants into shares and sold them to ICS at $2.62, or ICS bought the warrants from Murchison in the dark pool and then converted them into shares. Average ICS price per share: 2,62$

0 · Reply

SrTxan Nov. 14 at 12:48 PM

$BTAI On November 12, 2025 - BlackRock, Inc filed a 13F-HR form disclosing ownership of 84,282 shares of BioXcel Therapeutics, Inc. (US:BTAI) valued at $215,762 USD as of September 30, 2025. Average price per share: 2,56$

1 · Reply

SrTxan Nov. 14 at 12:09 PM

$BTAI On November 12, 2025 - Alpha Zero, Llc filed a 13F-HR form disclosing ownership of 19,574 shares of BioXcel Therapeutics, Inc. (US:BTAI) valued at $52,350, USD as of September 30, 2025. Average price per share: 2,67$

0 · Reply

SrTxan Nov. 14 at 12:02 PM

$BTAI Diversify Wealth Management, Llc ownership in BTAI / BioXcel Therapeutics, Inc. On November 12, 2025 - Diversify Wealth Management, Llc filed a 13F-HR form disclosing ownership of 15,000 shares of BioXcel Therapeutics, Inc. (US:BTAI) valued at $38,400 USD as of September 30, 2025. The entity filed a previous 13F-HR on August 14, 2025 disclosing 15,000 shares of BioXcel Therapeutics, Inc.. This represents a change in shares of 0.00% during the quarter. The current value of the position is $24,150 USD. Average price per share: 2.56$

0 · Reply

SrTxan Nov. 14 at 11:36 AM

$BTAI OAKTREE FUND ADVISORS 42.913 shares valued at 109.857$ Average price per share: 2.56$ 13 F-HR published today

0 · Reply

SrTxan Nov. 14 at 11:26 AM

$BTAI UBS Group AG reports 9.18% increase in ownership of BTAI / BioXcel Therapeutics, Inc. On November 13, 2025 - UBS Group AG filed a 13F-HR form disclosing ownership of 43,542 shares of BioXcel Therapeutics, Inc. (US:BTAI) valued at $111,468 USD as of September 30, 2025. The entity filed a previous 13F-HR on August 14, 2025 disclosing 39,882 shares of BioXcel Therapeutics, Inc.. This represents a change in shares of 9.18% during the quarter. The current value of the position is $70,103 USD. Average price per share: 2,56$

1 · Reply

SrTxan Nov. 14 at 11:16 AM

$BTAI While small investors are scared, the sharks keep buying. FMR LLC filed a Form 13F-HR yesterday for 198,600 shares of BTAI for a total price of $508,416. Average price per share: $2.56 https://www.sec.gov/edgar/search/#/q=bioxcel&ciks=0000315066&entityName=FMR%2520LLC%2520(CIK%25200000315066)&sort=desc

0 · Reply

SrTxan Nov. 14 at 10:48 AM

$BTAI Geode Capital Management, Llc reports 344.40% increase in ownership of BTAI / BioXcel Therapeutics, Inc. On November 12, 2025 - Geode Capital Management, Llc filed a 13F-HR form disclosing ownership of 125,240 shares of BioXcel Therapeutics, Inc. (US:BTAI) valued at $320,614 USD as of September 30, 2025. The entity filed a previous 13F-HR on August 8, 2025 disclosing 28,182 shares of BioXcel Therapeutics, Inc.. This represents a change in shares of 344.40% during the quarter. The current value of the position is $201,636 USD.

1 · Reply

Ernesto62 Nov. 14 at 10:27 AM

$BTAI good Kick

0 · Reply

GetOverHere_ Nov. 14 at 8:49 AM

$CRCE $KR $QMMM $BTAI +

0 · Reply

Market Cap	26.10M
Revenue (ttm)	2.27M
Net Income (ttm)	-59.60M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-2,625.55%
Debt to Equity Ratio	-1.01

Volume	585,600
Avg Vol	1,243,060
Day's Range	N/A - N/A
Shares Out	16.01M
Stochastic %K	19%
Beta	0.20
Analysts	Sell
Price Target	$9.67